You have accessJournal of UrologyHealth Services Research: Practice Patterns, Quality of Life and Shared Decision Making I (PD03)1 Sep 2021PD03-08 THE INTRODUCTION AND UPTAKE OF UROLIFT: A STUDY OF INDUSTRY PAYMENTS AND REIMBURSEMENT PATTERNS (2015-2018) Evan Garden, Nir Tomer, Micah Levy, Devki Shukla, Alexander Small, and Michael Palese Evan GardenEvan Garden More articles by this author , Nir TomerNir Tomer More articles by this author , Micah LevyMicah Levy More articles by this author , Devki ShuklaDevki Shukla More articles by this author , Alexander SmallAlexander Small More articles by this author , and Michael PaleseMichael Palese More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001967.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Prostatic urethral lift (UroLift, NeoTract Inc., Pleasanton, CA) is a minimally invasive procedure for benign prostatic hyperplasia (BPH). It was approved in 2013 and utilization has since increased dramatically. We sought to describe UroLift’s uptake and to explore any relationship between industry payments from NeoTract to physicians with rates of UroLift utilization. METHODS: Using the CMS Provider Utilization and Payment Database (2015-2018), all UroLift cases were identified for providers who performed >10 procedures annually (CPT Codes 52441, 52442). Providers who performed <10 of procedures are excluded from the database. These data were merged with Sunshine Act-reported payment data from NeoTract for each physician over the same interval. Differences in case volume and total Medicare reimbursement were evaluated based on receipt of payments. Spearman's rank correlation was used to test for association between payment amount and annual case volume. RESULTS: Medicare spending for UroLift increased more than 28-fold (2015-2018: $777,742.83 to $22,118,346.10), while mean annual reimbursement for providers rose by 11.6% (2015-2018: $33,814.91 to $37,744.62). For the 1,168 providers included, median industry payment was $243.50 (IQR: $45-$1,173). 171 providers received no payment. On average, this group performed fewer cases compared to providers who received industry payments (18.49 vs. 22.86, p<0.001). They also had lower annual reimbursement totals ($20,815.64 vs. $41,251.12, p<0.001). The fraction of providers who received no payment increased yearly (2015-2018: 4.35% to 16.55%). There was a small-but-significant correlation between industry payment amount and annual total Medicare reimbursement (R = 0.254, p<0.01) (Figure 1). CONCLUSIONS: Since its introduction, UroLift has seen a rapid uptake among urologists. Physician utilization of UroLift correlated positively with Sunshine Act-reported industry payments in a small-but-significant way. Source of Funding: N/A © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e45-e46 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Evan Garden More articles by this author Nir Tomer More articles by this author Micah Levy More articles by this author Devki Shukla More articles by this author Alexander Small More articles by this author Michael Palese More articles by this author Expand All Advertisement Loading ...